Informations sur les membres
Dr Johannes Birtel
Allemagne
Équipe
Pr Martin Spitzer
Allemagne
Centre de soins de santé
contact
Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany
Essais cliniques
A Phase 3, Randomized, International Multicenter Trial of DAY101 Monotherapy Versus Standard of Care Chemotherapy in Patients with Pediatric Low-Grade Glioma Harboring an Activating RAF Alteration Requiring First-Line Systemic Therapy
A Phase 3 Multicenter, Randomized, Double Masked, Sham- Controlled Clinical Trial to Assess the Safety and Efficacy of Intravitreal Administration of Zimura (Complement C5 Inhibitor) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration
A Phase 2b Pivotal Study to Evaluate the Efficacy and Safety of Izokibep in Subjects With Non-infectious, Intermediate-, Posterior- or Pan-uveitis
Avacincaptad Pegol Open-Label Extension for Patients With Geographic Atrophy
European Disease Registry on Retinopathy of Prematurity (ROP)
Retrospective Chart Review Study Combined with Cross-sectional Patient and Caregiver Surveys to Document and Describe the Disease-related Clinical, Individual, Sociodemographic Characteristics of Patients with X-linked Retinitis Pigmentosa (XLRP) and the Impact of XLRP on Patients and Their Caregivers
Early Reperfusion Therapy With Intravenous Alteplase for Recovery of VISION in Acute Central Retinal Artery Occlusion
A Phase III, Multicentre, International Study With a Parallel, Randomised, Double-blind, Placebo-controlled, 2 Arm Design to Assess the Efficacy and Safety of Selumetinib in Adult Participants With NF1 Who Have Symptomatic, Inoperable Plexiform Neurofibromas (KOMET)
An Open-label, Active-Controlled, Safety, and Efficacy Study of Oral Baricitinib in Patients From 2 Years to Less Than 18 Years Old With Active Juvenile Idiopathic Arthritis-Associated Uveitis or Chronic Anterior Antinuclear Antibody-Positive Uveitis
Vitrectomy, Subretinal Tissue Plasminogen Activator (TPA) and Intravitreal Gas for Submacular Haemorrhage Secondary to Exudative (Wet) Age-related Macular Degeneration (TIGER)
Pivotal 2 Study of RGX-314 Gene Therapy in Participants With nAMD (ASCENT)
A Study of the Efficacy, Safety, and Pharmacokinetics of A 36-Week Refill Regimen for the Port Delivery System With Ranibizumab in Patients With Neovascular Age-Related Macular Degeneration (Velodrome)
Multicentre Implementation and Validation of a Molecular Diagnostic for VitreoRetinal Lymphoma (DecodeVRL)